Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5438031 | 1.00 | CYP1A2 (0.39) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL5436252 | 1.00 | CYP1A2 (0.39) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL5437305 | 1.00 | CYP1A2 (0.39) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL6805031 | 1.00 | CYP1A2 (0.39) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL5441803 | 1.00 | CYP1A2 (0.39) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL6805426 | 1.00 | CYP1A2 (0.39) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL5437213 | 1.00 | CYP1A2 (0.39) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL16306576 | 0.90 | CYP1A2 (0.44) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL15308541 | 0.90 | CYP1A2 (0.44) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL15894815 | 0.84 | CYP1A2 (0.40) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160158247-A1 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors | OMEROS CORPORATION | 2016-06-09 | — | — | US | disclosed |
| US-20160015715-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | OMEROS CORPORATION | 2016-01-21 | — | — | US | disclosed |
| US-9220715-B2 | Treatment of addiction and impulse-control disorders using PDE7 inhibitors | OMEROS CORPORATION (US) | 2015-12-29 | — | — | US | disclosed |
| US-9119822-B2 | Use of PDE7 inhibitors for the treatment of movement disorders | OMEROS CORPORATION (US) | 2015-09-01 | — | — | US | disclosed |
| US-20140179717-A1 | Use of PDE7 Inhibitors for the Treatment of Movement Disorders | OMEROS CORPORATION (US) | 2014-06-26 | — | — | US | disclosed |
| US-8637528-B2 | Use of PDE7 inhibitors for the treatment of movement disorders | OMEROS CORPORATION (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130267502-A1 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors | OMEROS CORPORATION | 2013-10-10 | — | — | US | disclosed |
| WO-2007090661-A2 | ACTIVE SUBSTANCE COMBINATION COMPRISING AZOLYLCARBINOL COMPOUNDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-08-16 | — | — | WO | disclosed |
| US-7189747-B2 | Method of treating noninflammatory cartilage damage | WARNER-LAMBERT COMPANY (US) | 2007-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158247-A1 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors | PDE7B, PDE4C, PDE4A | CYP1A2 1067/4885USP2 631/4885ALDH1A1 886/4885 |
| US-20160015715-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | PARK7, PDE7B, PDE7A | CYP1A2 2696/4885USP2 795/4885ALDH1A1 1653/4885 |
| US-20140179717-A1 | Use of PDE7 Inhibitors for the Treatment of Movement Disorders | PARK7, PDE7B, PDE7A | CYP1A2 2696/4885USP2 795/4885ALDH1A1 1653/4885 |
| US-20130267502-A1 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors | PDE7B, PDE4C, PDE4A | CYP1A2 1067/4885USP2 631/4885ALDH1A1 886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.